{"title":"Voltaren","description":"\u003cp\u003eLa linea Voltaren a base di diclofenac per i dolori muscolari e articolari: Emulgel da spalmare sulla zona dolente in tubi da 60, 100, 120 e 180 grammi, cerotti medicati Voltadol a rilascio prolungato, schiuma cutanea Voltalgan e compresse e bustine Voltadvance da prendere per bocca. Per contratture, strappi, distorsioni, mal di schiena e dolori da artrosi. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"voltaren-emulgel-gel-60-gr-2","title":"Voltaren Emulgel Gel 60 Gr 2%","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature affecting the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons, and ligaments (such as tendinitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel\u003c\/i\u003e contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel); butylated hydroxytoluene (0.2 mg\/g of gel); pungent eucalyptus fragrance. For the full list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eButylated hydroxytoluene\u003c\/b\u003e, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, cetostearyl ether of macrogol, oleyl alcohol, \u003cb\u003epropylene glycol\u003c\/b\u003e, \u003cb\u003epungent eucalyptus fragrance\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria, or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cp\u003eFor cutaneous use.\u003c\/p\u003e \u003cb\u003eAdults over 18 years:\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e provides pain relief for up to 12 hours: Apply \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e twice a day to the area to be treated (preferably in the morning and evening), rubbing in lightly. The amount to apply depends on the size of the affected area. For example, 2–4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400–800 cm\u0026sup2;. After application, clean your hands with absorbent paper and then wash them, unless the hands are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before taking a shower or bath. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without a doctor's advice. Consult a doctor if symptoms persist or worsen after 7 days of treatment. \u003cb\u003eAdolescents from 14 to 18 years old:\u003c\/b\u003e Apply Voltaren Emulgel 2% gel twice a day to the area to be treated (preferably in the morning and evening), rubbing in gently. The amount to be applied depends on the size of the affected area. For example, 2-4 g of Voltaren Emulgel 2% gel (an amount ranging in size from a cherry to a walnut) is sufficient to treat an area of 400-800 cm\u0026sup2;. After application, clean hands with absorbent paper and then wash them, unless they are the site to be treated. The absorbent paper should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e There are insufficient data on the efficacy and safety in children and adolescents under 14 years (see paragraph 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. \u003cb\u003eElderly (over 65 years)\u003c\/b\u003e The usual adult dosage can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSTORAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large areas of skin and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should be applied only on intact, healthy skin, and not on skin wounds or open lesions. It should not come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if a skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g), equivalent to 50 mg\/g, which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g., contact dermatitis) or irritation of the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus fragrance, an aroma that in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eADVERSE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse effects include mild and transient skin reactions at the application site. In very rare cases, allergic reactions may occur. The adverse effects (Table 1) are listed below by organ, system, and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10); common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c1\/100); rare (≥ 1\/10,000 to \u003c1\/1,000); very rare (\u003c 1\/10,000); unknown (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e \u003ctable border=1 cellspacing=0 cellpadding=3\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eInfections and infestations\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Rash with pustules.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Hypersensitivity (including urticaria), angioedema.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eRespiratory, thoracic, and mediastinal disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Asthma.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd colspan=2\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e \u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Common\u003c\/td\u003e \u003ctd\u003e Dermatitis (including contact dermatitis), rash, erythema, eczema, itching.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Rare\u003c\/td\u003e \u003ctd\u003e Bullous dermatitis.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Very rare\u003c\/td\u003e \u003ctd\u003e Photosensitivity reaction, allergic reactions.\u003c\/td\u003e \u003c\/tr\u003e \u003ctr\u003e \u003ctd\u003e Unknown\u003c\/td\u003e \u003ctd\u003e Burning sensation at the application site, dry skin.\u003c\/td\u003e \u003c\/tr\u003e \u003c\/table\u003e \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e The reporting of suspected adverse reactions that occur after the medicinal product has been authorized is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are requested to report any suspected adverse reaction via the national reporting system at the address: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes an overdose very unlikely; however, adverse effects similar to those observed after an overdose of diclofenac tablets can be expected if Voltaren Emulgel 2% is ingested (1 tube of 60 g contains the equivalent of 1.2 g of diclofenac sodium). In case of ingestion leading to significant systemic adverse effects, general therapeutic measures normally adopted for treating poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment procedures, within a short time after ingestion, should take into account clinical indications or recommendations from the poison center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared with oral formulations is lower after topical administration. Referring to the experience with NSAID treatment via systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryonic\/fetal development. Results from epidemiological studies suggest an increased risk of miscarriage and of heart malformations and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of heart malformations increases from less than 1% to about 1.5%. It is believed that the risk increases with the dose and the duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and mortality. embryo-fetal; moreover, an increased incidence of various malformations, including cardiovascular ones, has been reported in animals that were administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman planning to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligohydramnios; the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-platelet effect that can occur even at very low doses; - inhibition of uterine contractions resulting in delay or prolongation of labor. Diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at the therapeutic doses of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this case, \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see paragraph 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON ABILITY TO DRIVE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e does not impair the ability to drive vehicles or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":40207823929459,"sku":"034548065","price":13.67,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-60-gr-2-farmacia-dottor-tili-1213792743.webp?v=1767125980"},{"product_id":"voltaren-emulgel-gel-2-100-gr","title":"Voltaren Emulgel Gel 2% 100 Gr","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel\u003c\/i\u003e contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); butylated hydroxytoluene (0.2 mg\/g of gel); pungent eucalyptus perfume For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eButylated hydroxytoluene\u003c\/b\u003e, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, \u003cb\u003epropylene glycol\u003c\/b\u003e, \u003cb\u003epungent eucalyptus scent\u003c\/b\u003e, purified water.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • History of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • During the third trimester of pregnancy. • Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e provides pain relief for up to 12 hours: Apply \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Caution: Use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. \u003cb\u003eAdolescents aged 14 to 18:\u003c\/b\u003e Apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (a quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years of age (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. \u003cb\u003eElderly (over 65 years old)\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e cannot be excluded if the preparation is used on large skin areas and for a prolonged period\u003ci\u003e.\u003c\/i\u003e \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it must only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. \u003ci\u003eVoltaren Emulgel 2% gel\u003c\/i\u003e contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Undesirable effects (Table 1) are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10) common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioedema.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely; however side effects similar to those observed after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected just in case \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e is ingested (1 60 g tube contains the equivalent of 1.2 g of diclofenac sodium). In case of ingestion, which gives rise to significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increases from less than 1% to approximately 1.5%. The risk is believed to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality; furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors had been administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eVoltaren Emulgel 2%\u003c\/i\u003e does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":46369425260871,"sku":"034548154","price":17.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/novartis-farma-spa-voltaren-emulgel-gel-2-100-gr-farmacia-dottor-tili-1213792507.jpg?v=1767112290"},{"product_id":"voltadvance-20-compresse-rivestite-25mg","title":"Voltadvance 20 Coated Tablets 25mg","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of various kinds such as, for example, joint pain, lumbago, muscle pain, headaches and toothaches, menstrual pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne film-coated tablet contains\u003c\/u\u003e: active ingredient diclofenac sodium 25 mg. \u003cu\u003eOne sachet of powder for oral solution contains\u003c\/u\u003e: active ingredient diclofenac sodium 25 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: flavors containing limonene, linalool, eugenol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFilm-coated tablets\u003c\/i\u003e: potassium bicarbonate; mannitol; sodium lauryl sulfate; crospovidone; magnesium stearate; glycerol dibeenate; Clear Opadry (hypromellose; macrogol). \u003ci\u003ePowder for oral solution\u003c\/i\u003e: potassium bicarbonate; mannitol; acesulfame potassium; glycerol dibeenate; mint flavor (containing limonene, linalool, eugenol); anise aroma (containing limonene and linalool).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Active gastrointestinal ulcer, bleeding or perforation. • History of gastrointestinal hemorrhage or perforation related to previous NSAID treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). • Last trimester of pregnancy and during breastfeeding (see section 4.6). • Severe hepatic insufficiency or severe renal insufficiency (see section 4.4). • Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom asthmatic attacks, urticaria, angioedema or acute rhinitis, anaphylactic or anaphylactoid reactions have occurred after taking acetylsalicylic acid or other NSAIDs (see section 4.4). • The product must not be used in case of alterations of haematopoiesis. • In case of intensive diuretic therapy. • The product must not be taken in case of dark or bloody stools. • Overt congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease and\/or cerebral vasculopathy. \u003cb\u003eVoltadvance should not be given to children under 14 years of age.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults and adolescents over 14 years\u003c\/b\u003e: 1-3 coated tablets or powder sachets for oral solution per day, with meals, even 2 in a single administration. The maximum daily dose is 75 mg. Do not exceed the recommended doses; in particular elderly patients must adhere to the minimum dosages indicated above. The coated tablets should be swallowed whole, with water or another liquid; the powder sachets should be dissolved in a glass of water before taking. We recommend taking the product preferably on a full stomach. Do not exceed 3 days of treatment. Undesirable effects can be minimized by administering the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). \u003cb\u003e \u003cu\u003eSpecial populations\u003c\/u\u003e \u003c\/b\u003e \u003cb\u003eRenal failure\u003c\/b\u003e Voltadvance is contraindicated in patients with severe renal impairment (see section 4.3). Caution is recommended when administering Voltadvance to patients with mild to moderate renal impairment (see section 4.4). \u003cb\u003eLiver failure\u003c\/b\u003e Voltadvance is contraindicated in patients with severe hepatic impairment (see section 4.3). Caution is recommended when administering Voltadvance to patients with mild to moderate hepatic impairment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAfter 2-3 days of treatment without appreciable results, consult your doctor. \u003cb\u003eGeneral information\u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). The use of diclofenac concomitantly with other systemic NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to the lack of any evidence demonstrating synergistic benefits and on the basis of potential additive side effects. On a basic medical level, caution is required in the elderly. In particular in frail elderly patients or those with low body weight, the use of the lowest effective dose is recommended. As with other NSAIDs, allergic reactions, including anaphylactic\/anaphylactoid reactions, may also occur in rare cases without prior exposure to diclofenac. Hypersensitivity reactions can also progress to Kounis syndrome, a severe allergic reaction that can cause a myocardial infarction. Symptoms of such reactions may include chest pain that occurs in association with an allergic reaction to diclofenac. Like other NSAIDs, diclofenac may mask the signs and symptoms of infections due to its pharmacodynamic properties. Prolonged use of any type of pain reliever for headaches can make them worse. If this situation has occurred or is suspected, medical advice should be sought and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite regular use of headache medications. \u003cb\u003eGastrointestinal effects\u003c\/b\u003e Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported during treatment with all NSAIDs, including diclofenac, and may appear at any time, with or without warning symptoms or previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving diclofenac, the medicinal product should be discontinued. As with all NSAIDs, including diclofenac, close medical surveillance is mandatory and particular caution should be used when prescribing diclofenac to patients with symptoms suggestive of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation, inflammatory bowel disease (see section 4.8). The risk of GI bleeding is higher with increased doses of NSAIDs and in patients with a history of ulcer, especially if complicated by hemorrhage or perforation. Elderly people have a higher frequency of adverse reactions, especially gastrointestinal bleeding and perforation which can be fatal. To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated by haemorrhage or perforation, and in the elderly treatment should be initiated and maintained at the lowest effective dose. The concomitant use of protective agents (proton pump inhibitors or misoprostol) should be considered for these patients and also for patients who require concomitant use of medicinal products containing low doses of acetylsalicylic acid (ASA) or other medicinal products that may increase gastrointestinal risk. Patients with a history of GI toxicity, particularly older adults, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients taking concomitant medicinal products that may increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, antiplatelet agents or selective serotonin reuptake inhibitors (see section 4.5). Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease as these conditions may be exacerbated (see section 4.8). NSAIDs, including diclofenac, may be associated with an increased risk of leakage from gastrointestinal anastomoses. Caution and close medical surveillance are recommended when using diclofenac following gastrointestinal surgery. \u003cb\u003eHepatobiliary effects\u003c\/b\u003e When prescribing diclofenac to patients with liver failure, close medical supervision is necessary as their condition may be exacerbated. As with other NSAIDs, including diclofenac, they may increase the values ​​of one or more liver enzymes. During prolonged treatment with diclofenac, regular checks of liver function are indicated as a precautionary measure. If liver function parameters are persistently altered or worsened, if clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (e.g. eosinophilia, rash), treatment with diclofenac should be discontinued. Hepatitis with the use of diclofenac can occur without prodromal symptoms. Particular caution should be exercised when using diclofenac in patients with hepatic porphyria, as they may trigger an attack. \u003cb\u003eRenal effects\u003c\/b\u003e Since fluid retention and edema have been reported in association with therapy with NSAIDs, including diclofenac, particular caution is required in cases of renal insufficiency, history of hypertension, in the elderly, in patients receiving concomitant treatment with diuretics or with medicinal products that can significantly affect renal function and in those patients with substantial extracellular volume depletion due to any cause (e.g. before or after major surgery) (see section 4.3). In such cases, monitoring of renal function is recommended as a precaution when administering diclofenac. Interruption of therapy is normally followed by a return to pre-treatment conditions. \u003cb\u003eSkin effects\u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk for these reactions: the onset of the reaction occurs in most cases within the first month of treatment. Voltadvance should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eCardiovascular and cerebrovascular effects\u003c\/b\u003e Clinical trials and epidemiological data consistently indicate an increased risk of arterial thrombotic events (for example, myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment. Patients with significant risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking) should be treated with diclofenac only after careful consideration. Patients with congestive heart failure (NYHA class I) should be treated with diclofenac only after careful consideration. Since the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest possible duration and lowest effective daily dose should be used. Patients should be advised to consult their doctor if symptoms persist or do not improve within the recommended treatment duration. Patients should be alert for signs and symptoms of serious thrombotic events (e.g., chest pain, shortness of breath, weakness, slurred speech), which may occur without warning symptoms. Patients should be advised to contact a doctor immediately if any of these events occur. \u003cb\u003eHematological effects\u003c\/b\u003e During prolonged treatment with diclofenac, as with other NSAIDs, blood count checks are recommended. Like other NSAIDs, diclofenac can temporarily inhibit platelet aggregation. Patients with defects in hemostasis must be carefully monitored. \u003cb\u003eRespiratory effects (pre-existing asthma)\u003c\/b\u003e In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (e.g. nasal polyps), chronic obstructive pulmonary diseases or chronic respiratory tract infections (especially if linked to symptoms similar to allergic rhinitis), reactions to NSAIDs such as asthma exacerbations (so-called intolerance to analgesics\/analgesic asthma), Quincke's edema or urticaria are more frequent than in other patients. Special precaution is therefore recommended in such patients (prepare for an emergency). This also applies to patients allergic to other substances, e.g. with skin reactions, itching or hives. \u003cb\u003eImportant information about some excipients:\u003c\/b\u003e Voltadvance 25 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'. Voltadvance 25 mg powder for oral solution contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Voltadvance 25 mg powder for oral solution contains the anise flavor which in turn contains limonene and linalool. Limonene and linalool can cause allergic reactions. Voltadvance 25 mg powder for oral solution contains the mint flavor which in turn contains limonene, linalool and eugenol. Limonene, linalool and eugenol can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBefore using the product, if you are taking other medications, it is advisable to inform your doctor as it may be necessary to change the dosage or interrupt the treatment. The following interactions include those observed with diclofenac gastro-resistant tablets and\/or other pharmaceutical forms of diclofenac. \u003cb\u003eLithium\u003c\/b\u003e: If administered concomitantly, diclofenac may elevate plasma lithium concentrations. Monitoring of serum lithium levels is recommended. \u003cb\u003eDigoxin\u003c\/b\u003e: If administered concomitantly, diclofenac may elevate plasma concentrations of digoxin. Monitoring of serum digoxin levels is recommended. \u003cb\u003eDiuretics and antihypertensive agents\u003c\/b\u003e: Patients undergoing treatment with these drugs should consult their doctor before taking the product. Like other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensive agents (e.g. beta blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in their antihypertensive effect. Therefore, the combination should be taken with caution and patients, especially elderly people, should receive periodic monitoring of their blood pressure. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors due to an increased risk of nephrotoxicity. \u003cb\u003eOther NSAIDs and corticosteroids\u003c\/b\u003e: Concomitant use of diclofenac and other systemic non-steroidal anti-inflammatory drugs or corticosteroids may increase the incidence of gastrointestinal side effects and should be avoided (see section 4.4). \u003cb\u003eAnticoagulants and antiplatelet agents\u003c\/b\u003e: Caution is recommended, as concomitant administration may increase the risk of bleeding. Although clinical investigations do not appear to indicate an influence of diclofenac on the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients taking diclofenac and anticoagulants concomitantly. Careful monitoring of such patients is therefore recommended. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: co-administration of systemic NSAIDs, including diclofenac, and SSRIs may increase the risk of gastrointestinal bleeding (see section 4.4). \u003cb\u003eAntidiabetics\u003c\/b\u003e: Clinical studies have shown that diclofenac can be administered together with oral antidiabetics without influencing their clinical effect. However, isolated cases of both hypo- and hyperglycaemic effects have been reported, with the need to modify the dosage of antidiabetic agents administered during treatment with diclofenac. For this reason, in case of concomitant therapy, monitoring of blood glucose levels is recommended as a precautionary measure. Some cases of metabolic acidosis have also been reported when diclofenac was co-administered with metformin, especially in patients with pre-existing renal insufficiency. \u003cb\u003eMethotrexate\u003c\/b\u003e: diclofenac may inhibit renal tubular release of methotrexate by increasing its levels. Caution is recommended when administering NSAIDs, including diclofenac, 24 hours before or after treatment with methotrexate since blood concentrations of methotrexate and consequently the toxicity of this substance may increase. \u003cb\u003eCyclosporine\u003c\/b\u003e: due to its effect on renal prostaglandins, diclofenac, like other NSAIDs, can increase the nephrotoxicity of ciclosporin. Therefore, diclofenac should be administered at doses lower than those used in patients not receiving ciclosporin. \u003cb\u003eDrugs known to cause hyperkalemia\u003c\/b\u003e: Concomitant treatment with potassium-sparing diuretic drugs, ciclosporin, tacrolimus or trimethoprim may be associated with an increase in serum potassium levels, which should therefore be monitored frequently (see section 4.4). \u003cb\u003eQuinolone antibacterials\u003c\/b\u003e: Isolated cases of convulsions have been reported, probably due to the concomitant use of quinolones and NSAIDs. \u003cb\u003ePhenytoin\u003c\/b\u003e: When using phenytoin together with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to a predictable increase in phenytoin exposure. \u003cb\u003eColestipol and cholestyramine\u003c\/b\u003e: these agents may induce a delay or decrease in the absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4-6 hours after the administration of colestipol\/cholestyramine. \u003cb\u003eCYP2C9 inhibitors\u003c\/b\u003e: Caution is recommended when prescribing diclofenac together with CYP2C9 inhibitors (such as sulfinpyrazone and voriconazole); this may lead to a significant increase in peak plasma concentrations and exposure to diclofenac, due to the inhibition of its metabolism. Diclofenac may also decrease the effectiveness of intrauterine devices and the risk of interferon alpha inhibition has been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects (Table 1) are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10); common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known (frequency cannot be estimated from the available data). The following side effects include those reported with short-term or long-term use. If one of these effects should appear during treatment with Voltadvance, it is advisable to discontinue the drug and consult your doctor. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eVery rare: thrombocytopenia, leukopenia, anemia (including haemolytic and aplastic anemia), agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare: hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).\u003c\/p\u003e\n\u003cp\u003eVery rare: angioedema (including facial edema).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: disorientation, depression, insomnia, nightmares, irritability, psychotic reactions.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eRare: drowsiness.\u003c\/p\u003e\n\u003cp\u003eVery rare: paresthesia, memory impairment, convulsions, anxiety, tremors, aseptic meningitis, taste changes, cerebrovascular accidents.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: visual disturbances, blurred vision, diplopia.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: dizziness.\u003c\/p\u003e\n\u003cp\u003eVery rare: tinnitus, hearing worsening.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eUncommon*: Myocardial infarction, heart failure, palpitations, chest pain.\u003c\/p\u003e\n\u003cp\u003eNot known: Kounis syndrome.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: hypertension, vasculitis.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare: asthma (including dyspnoea).\u003c\/p\u003e\n\u003cp\u003eVery rare: pneumonia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.\u003c\/p\u003e\n\u003cp\u003eRare: gastritis, gastrointestinal haemorrhage, haematemesis, haemorrhagic diarrhoea, melena, gastrointestinal ulcer (with or without bleeding or perforation, which may lead to peritonitis), dry mouth and mucous membranes, gastrointestinal stenosis.\u003c\/p\u003e\n\u003cp\u003eVery rare: colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorders, intestinal diaphragm disease, pancreatitis, constipation.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: increased transaminases.\u003c\/p\u003e\n\u003cp\u003eRare: hepatitis, jaundice, liver disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: fulminant hepatitis, hepatic necrosis, hepatic failure.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: rash.\u003c\/p\u003e\n\u003cp\u003eRare: urticaria.\u003c\/p\u003e\n\u003cp\u003eVery rare: bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), exfoliative dermatitis, hair loss, photosensitivity reaction, purpura, Henoch-Schonlein purpura, pruritus.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: acute renal failure, haematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eRare: edema.\u003c\/p\u003e\n\u003cp\u003e* Frequency reflects data from long-term treatment with a high dose (150 mg per day). Clinical trials and epidemiological data consistently indicate an increased risk of arterial thrombotic events (for example, myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment (for contraindications and special warnings and precautions for use see sections 4.3 and 4.4). \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e There is no typical clinical picture resulting from an overdose of diclofenac. Overdose may cause symptoms such as vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus or seizures. In case of significant poisoning, acute renal failure and liver damage are possible. \u003cb\u003eTherapeutic measures\u003c\/b\u003e Treatment of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. In case of complications such as hypotension, renal failure, convulsions, gastrointestinal disorders and respiratory depression, supportive measures and symptomatic treatment should be adopted. Specific therapies, such as forced diuresis, dialysis or hemoperfusion, are probably not helpful in eliminating NSAIDs, including diclofenac, due to their high binding to plasma proteins and their considerable metabolism. Further treatment modalities should take into account clinical indications or poison control center recommendation, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. From the 20th\u003csup\u003ea\u003c\/sup\u003e week of pregnancy onwards, the use of diclofenac could cause oligohydramnios resulting from fetal renal dysfunction. This condition may be experienced shortly after starting treatment and is usually reversible upon discontinuation of treatment. Furthermore, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester of pregnancy, most of which disappeared after discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment should be as short as possible. Following exposure to diclofenac for several days from the 20th\u003csup\u003ea\u003c\/sup\u003e week of gestation onwards, antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered. In case of oligohydramnios or constriction of the ductus arteriosus, treatment with diclofenac should be discontinued. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose - the fetus to: - cardiopulmonary toxicity (constriction\/premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction (see above), which may progress to renal failure with oligo-hydramnios; - the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. Therefore, diclofenac should not be administered during breastfeeding to avoid side effects in the infant. \u003cb\u003eFertility\u003c\/b\u003e As with other NSAIDs, the use of diclofenac can alter female fertility and is not recommended in women wishing to conceive. Discontinuation of diclofenac should be considered in women who have difficulty conceiving or who are undergoing infertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients in whom vision disturbances, dizziness, vertigo, drowsiness or other central nervous system disorders have occurred with the use of diclofenac should refrain from driving vehicles or using machinery.\u003c\/p\u003e","brand":"Gsk","offers":[{"title":"Default Title","offer_id":46473235398983,"sku":"035500026","price":11.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/glaxosmithkline-c-health-srl-voltadvance-20-compresse-rivestite-25mg-farmacia-dottor-tili-1213792495.jpg?v=1767112463"},{"product_id":"voltadvance-25mg-20-bustine-polvere-per-soluzione-orale","title":"Voltadvance 25mg 20 sachets powder for oral solution","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePain of various kinds such as, for example, joint pain, lumbago, muscle pain, headaches and toothaches, menstrual pain.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eOne film-coated tablet contains\u003c\/u\u003e: active ingredient diclofenac sodium 25 mg. \u003cu\u003eOne sachet of powder for oral solution contains\u003c\/u\u003e: active ingredient diclofenac sodium 25 mg. \u003cu\u003eExcipients with known effects\u003c\/u\u003e: flavors containing limonene, linalool, eugenol. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFilm-coated tablets\u003c\/i\u003e: potassium bicarbonate; mannitol; sodium lauryl sulfate; crospovidone; magnesium stearate; glycerol dibeenate; Clear Opadry (hypromellose; macrogol). \u003ci\u003ePowder for oral solution\u003c\/i\u003e: potassium bicarbonate; mannitol; acesulfame potassium; glycerol dibeenate; mint flavor (containing limonene, linalool, eugenol); anise aroma (containing limonene and linalool).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Active gastrointestinal ulcer, bleeding or perforation. • History of gastrointestinal hemorrhage or perforation related to previous NSAID treatment or history of recurrent peptic hemorrhage\/ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). • Last trimester of pregnancy and during breastfeeding (see section 4.6). • Severe hepatic insufficiency or severe renal insufficiency (see section 4.4). • Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom asthmatic attacks, urticaria, angioedema or acute rhinitis, anaphylactic or anaphylactoid reactions have occurred after taking acetylsalicylic acid or other NSAIDs (see section 4.4). • The product must not be used in case of alterations of haematopoiesis. • In case of intensive diuretic therapy. • The product must not be taken in case of dark or bloody stools. • Overt congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease and\/or cerebral vasculopathy. \u003cb\u003eVoltadvance should not be given to children under 14 years of age.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults and adolescents over 14 years\u003c\/b\u003e: 1-3 coated tablets or powder sachets for oral solution per day, with meals, even 2 in a single administration. The maximum daily dose is 75 mg. Do not exceed the recommended doses; in particular elderly patients must adhere to the minimum dosages indicated above. The coated tablets should be swallowed whole, with water or another liquid; the powder sachets should be dissolved in a glass of water before taking. We recommend taking the product preferably on a full stomach. Do not exceed 3 days of treatment. Undesirable effects can be minimized by administering the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). \u003cb\u003e \u003cu\u003eSpecial populations\u003c\/u\u003e \u003c\/b\u003e \u003cb\u003eRenal failure\u003c\/b\u003e Voltadvance is contraindicated in patients with severe renal impairment (see section 4.3). Caution is recommended when administering Voltadvance to patients with mild to moderate renal impairment (see section 4.4). \u003cb\u003eLiver failure\u003c\/b\u003e Voltadvance is contraindicated in patients with severe hepatic impairment (see section 4.3). Caution is recommended when administering Voltadvance to patients with mild to moderate hepatic impairment (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAfter 2-3 days of treatment without appreciable results, consult your doctor. \u003cb\u003eGeneral information\u003c\/b\u003e Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular risks). The use of diclofenac concomitantly with other systemic NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to the lack of any evidence demonstrating synergistic benefits and on the basis of potential additive side effects. On a basic medical level, caution is required in the elderly. In particular in frail elderly patients or those with low body weight, the use of the lowest effective dose is recommended. As with other NSAIDs, allergic reactions, including anaphylactic\/anaphylactoid reactions, may also occur in rare cases without prior exposure to diclofenac. Hypersensitivity reactions can also progress to Kounis syndrome, a severe allergic reaction that can cause a myocardial infarction. Symptoms of such reactions may include chest pain that occurs in association with an allergic reaction to diclofenac. Like other NSAIDs, diclofenac may mask the signs and symptoms of infections due to its pharmacodynamic properties. Prolonged use of any type of pain reliever for headaches can make them worse. If this situation has occurred or is suspected, medical advice should be sought and treatment should be discontinued. The diagnosis of medication overuse headache (MOH) should be suspected in patients who have frequent or daily headaches despite regular use of headache medications. \u003cb\u003eGastrointestinal effects\u003c\/b\u003e Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported during treatment with all NSAIDs, including diclofenac, and may appear at any time, with or without warning symptoms or previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving diclofenac, the medicinal product should be discontinued. As with all NSAIDs, including diclofenac, close medical surveillance is mandatory and particular caution should be used when prescribing diclofenac to patients with symptoms suggestive of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation, inflammatory bowel disease (see section 4.8). The risk of GI bleeding is higher with increased doses of NSAIDs and in patients with a history of ulcer, especially if complicated by hemorrhage or perforation. Elderly people have a higher frequency of adverse reactions, especially gastrointestinal bleeding and perforation which can be fatal. To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated by haemorrhage or perforation, and in the elderly treatment should be initiated and maintained at the lowest effective dose. The concomitant use of protective agents (proton pump inhibitors or misoprostol) should be considered for these patients and also for patients who require concomitant use of medicinal products containing low doses of acetylsalicylic acid (ASA) or other medicinal products that may increase gastrointestinal risk. Patients with a history of GI toxicity, particularly older adults, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients taking concomitant medicinal products that may increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, antiplatelet agents or selective serotonin reuptake inhibitors (see section 4.5). Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease as these conditions may be exacerbated (see section 4.8). NSAIDs, including diclofenac, may be associated with an increased risk of leakage from gastrointestinal anastomoses. Caution and close medical surveillance are recommended when using diclofenac following gastrointestinal surgery. \u003cb\u003eHepatobiliary effects\u003c\/b\u003e When prescribing diclofenac to patients with liver failure, close medical supervision is necessary as their condition may be exacerbated. As with other NSAIDs, including diclofenac, they may increase the values ​​of one or more liver enzymes. During prolonged treatment with diclofenac, regular checks of liver function are indicated as a precautionary measure. If liver function parameters are persistently altered or worsened, if clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (e.g. eosinophilia, rash), treatment with diclofenac should be discontinued. Hepatitis with the use of diclofenac can occur without prodromal symptoms. Particular caution should be exercised when using diclofenac in patients with hepatic porphyria, as they may trigger an attack. \u003cb\u003eRenal effects\u003c\/b\u003e Since fluid retention and edema have been reported in association with therapy with NSAIDs, including diclofenac, particular caution is required in cases of renal insufficiency, history of hypertension, in the elderly, in patients receiving concomitant treatment with diuretics or with medicinal products that can significantly affect renal function and in those patients with substantial extracellular volume depletion due to any cause (e.g. before or after major surgery) (see section 4.3). In such cases, monitoring of renal function is recommended as a precaution when administering diclofenac. Interruption of therapy is normally followed by a return to pre-treatment conditions. \u003cb\u003eSkin effects\u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy, patients appear to be at higher risk for these reactions: the onset of the reaction occurs in most cases within the first month of treatment. Voltadvance should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eCardiovascular and cerebrovascular effects\u003c\/b\u003e Clinical trials and epidemiological data consistently indicate an increased risk of arterial thrombotic events (for example, myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment. Patients with significant risk factors for cardiovascular events (e.g., hypertension, hyperlipidemia, diabetes mellitus, smoking) should be treated with diclofenac only after careful consideration. Patients with congestive heart failure (NYHA class I) should be treated with diclofenac only after careful consideration. Since the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest possible duration and lowest effective daily dose should be used. Patients should be advised to consult their doctor if symptoms persist or do not improve within the recommended treatment duration. Patients should be alert for signs and symptoms of serious thrombotic events (e.g., chest pain, shortness of breath, weakness, slurred speech), which may occur without warning symptoms. Patients should be advised to contact a doctor immediately if any of these events occur. \u003cb\u003eHematological effects\u003c\/b\u003e During prolonged treatment with diclofenac, as with other NSAIDs, blood count checks are recommended. Like other NSAIDs, diclofenac can temporarily inhibit platelet aggregation. Patients with defects in hemostasis must be carefully monitored. \u003cb\u003eRespiratory effects (pre-existing asthma)\u003c\/b\u003e In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (e.g. nasal polyps), chronic obstructive pulmonary diseases or chronic respiratory tract infections (especially if linked to symptoms similar to allergic rhinitis), reactions to NSAIDs such as asthma exacerbations (so-called intolerance to analgesics\/analgesic asthma), Quincke's edema or urticaria are more frequent than in other patients. Special precaution is therefore recommended in such patients (prepare for an emergency). This also applies to patients allergic to other substances, e.g. with skin reactions, itching or hives. \u003cb\u003eImportant information about some excipients:\u003c\/b\u003e Voltadvance 25 mg film-coated tablets contain less than 1 mmol sodium (23 mg) per dose, i.e. essentially 'sodium-free'. Voltadvance 25 mg powder for oral solution contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially 'sodium-free'. Voltadvance 25 mg powder for oral solution contains the anise flavor which in turn contains limonene and linalool. Limonene and linalool can cause allergic reactions. Voltadvance 25 mg powder for oral solution contains the mint flavor which in turn contains limonene, linalool and eugenol. Limonene, linalool and eugenol can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBefore using the product, if you are taking other medications, it is advisable to inform your doctor as it may be necessary to change the dosage or interrupt the treatment. The following interactions include those observed with diclofenac gastro-resistant tablets and\/or other pharmaceutical forms of diclofenac. \u003cb\u003eLithium\u003c\/b\u003e: If administered concomitantly, diclofenac may elevate plasma lithium concentrations. Monitoring of serum lithium levels is recommended. \u003cb\u003eDigoxin\u003c\/b\u003e: If administered concomitantly, diclofenac may elevate plasma concentrations of digoxin. Monitoring of serum digoxin levels is recommended. \u003cb\u003eDiuretics and antihypertensive agents\u003c\/b\u003e: Patients undergoing treatment with these drugs should consult their doctor before taking the product. Like other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensive agents (e.g. beta blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a decrease in their antihypertensive effect. Therefore, the combination should be taken with caution and patients, especially elderly people, should receive periodic monitoring of their blood pressure. Patients should be adequately hydrated and monitoring of renal function should be considered after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors due to an increased risk of nephrotoxicity. \u003cb\u003eOther NSAIDs and corticosteroids\u003c\/b\u003e: Concomitant use of diclofenac and other systemic non-steroidal anti-inflammatory drugs or corticosteroids may increase the incidence of gastrointestinal side effects and should be avoided (see section 4.4). \u003cb\u003eAnticoagulants and antiplatelet agents\u003c\/b\u003e: Caution is recommended, as concomitant administration may increase the risk of bleeding. Although clinical investigations do not appear to indicate an influence of diclofenac on the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients taking diclofenac and anticoagulants concomitantly. Careful monitoring of such patients is therefore recommended. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs)\u003c\/b\u003e: co-administration of systemic NSAIDs, including diclofenac, and SSRIs may increase the risk of gastrointestinal bleeding (see section 4.4). \u003cb\u003eAntidiabetics\u003c\/b\u003e: Clinical studies have shown that diclofenac can be administered together with oral antidiabetics without influencing their clinical effect. However, isolated cases of both hypo- and hyperglycaemic effects have been reported, with the need to modify the dosage of antidiabetic agents administered during treatment with diclofenac. For this reason, in case of concomitant therapy, monitoring of blood glucose levels is recommended as a precautionary measure. Some cases of metabolic acidosis have also been reported when diclofenac was co-administered with metformin, especially in patients with pre-existing renal insufficiency. \u003cb\u003eMethotrexate\u003c\/b\u003e: diclofenac may inhibit renal tubular release of methotrexate by increasing its levels. Caution is recommended when administering NSAIDs, including diclofenac, 24 hours before or after treatment with methotrexate since blood concentrations of methotrexate and consequently the toxicity of this substance may increase. \u003cb\u003eCyclosporine\u003c\/b\u003e: due to its effect on renal prostaglandins, diclofenac, like other NSAIDs, can increase the nephrotoxicity of ciclosporin. Therefore, diclofenac should be administered at doses lower than those used in patients not receiving ciclosporin. \u003cb\u003eDrugs known to cause hyperkalemia\u003c\/b\u003e: Concomitant treatment with potassium-sparing diuretic drugs, ciclosporin, tacrolimus or trimethoprim may be associated with an increase in serum potassium levels, which should therefore be monitored frequently (see section 4.4). \u003cb\u003eQuinolone antibacterials\u003c\/b\u003e: Isolated cases of convulsions have been reported, probably due to the concomitant use of quinolones and NSAIDs. \u003cb\u003ePhenytoin\u003c\/b\u003e: When using phenytoin together with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to a predictable increase in phenytoin exposure. \u003cb\u003eColestipol and cholestyramine\u003c\/b\u003e: these agents may induce a delay or decrease in the absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4-6 hours after the administration of colestipol\/cholestyramine. \u003cb\u003eCYP2C9 inhibitors\u003c\/b\u003e: Caution is recommended when prescribing diclofenac together with CYP2C9 inhibitors (such as sulfinpyrazone and voriconazole); this may lead to a significant increase in peak plasma concentrations and exposure to diclofenac, due to the inhibition of its metabolism. Diclofenac may also decrease the effectiveness of intrauterine devices and the risk of interferon alpha inhibition has been reported.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects (Table 1) are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (≥ 1\/10); common (≥ 1\/100 to \u003c1\/10); uncommon (≥ 1\/1,000 to \u003c 1\/100); rare (≥ 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known (frequency cannot be estimated from the available data). The following side effects include those reported with short-term or long-term use. If one of these effects should appear during treatment with Voltadvance, it is advisable to discontinue the drug and consult your doctor. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eVery rare: thrombocytopenia, leukopenia, anemia (including haemolytic and aplastic anemia), agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare: hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).\u003c\/p\u003e\n\u003cp\u003eVery rare: angioedema (including facial edema).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: disorientation, depression, insomnia, nightmares, irritability, psychotic reactions.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eRare: drowsiness.\u003c\/p\u003e\n\u003cp\u003eVery rare: paresthesia, memory impairment, convulsions, anxiety, tremors, aseptic meningitis, taste changes, cerebrovascular accidents.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: visual disturbances, blurred vision, diplopia.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: dizziness.\u003c\/p\u003e\n\u003cp\u003eVery rare: tinnitus, hearing worsening.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eUncommon*: Myocardial infarction, heart failure, palpitations, chest pain.\u003c\/p\u003e\n\u003cp\u003eNot known: Kounis syndrome.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: hypertension, vasculitis.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare: asthma (including dyspnoea).\u003c\/p\u003e\n\u003cp\u003eVery rare: pneumonia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.\u003c\/p\u003e\n\u003cp\u003eRare: gastritis, gastrointestinal haemorrhage, haematemesis, haemorrhagic diarrhoea, melena, gastrointestinal ulcer (with or without bleeding or perforation, which may lead to peritonitis), dry mouth and mucous membranes, gastrointestinal stenosis.\u003c\/p\u003e\n\u003cp\u003eVery rare: colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorders, intestinal diaphragm disease, pancreatitis, constipation.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: increased transaminases.\u003c\/p\u003e\n\u003cp\u003eRare: hepatitis, jaundice, liver disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: fulminant hepatitis, hepatic necrosis, hepatic failure.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: rash.\u003c\/p\u003e\n\u003cp\u003eRare: urticaria.\u003c\/p\u003e\n\u003cp\u003eVery rare: bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), exfoliative dermatitis, hair loss, photosensitivity reaction, purpura, Henoch-Schonlein purpura, pruritus.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: acute renal failure, haematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eRare: edema.\u003c\/p\u003e\n\u003cp\u003e* Frequency reflects data from long-term treatment with a high dose (150 mg per day). Clinical trials and epidemiological data consistently indicate an increased risk of arterial thrombotic events (for example, myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment (for contraindications and special warnings and precautions for use see sections 4.3 and 4.4). \u003cb\u003e \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system: www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e There is no typical clinical picture resulting from an overdose of diclofenac. Overdose may cause symptoms such as vomiting, gastrointestinal bleeding, diarrhea, dizziness, tinnitus or seizures. In case of significant poisoning, acute renal failure and liver damage are possible. \u003cb\u003eTherapeutic measures\u003c\/b\u003e Treatment of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment. In case of complications such as hypotension, renal failure, convulsions, gastrointestinal disorders and respiratory depression, supportive measures and symptomatic treatment should be adopted. Specific therapies, such as forced diuresis, dialysis or hemoperfusion, are probably not helpful in eliminating NSAIDs, including diclofenac, due to their high binding to plasma proteins and their considerable metabolism. Further treatment modalities should take into account clinical indications or poison control center recommendation, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. From the 20th\u003csup\u003ea\u003c\/sup\u003e week of pregnancy onwards, the use of diclofenac could cause oligohydramnios resulting from fetal renal dysfunction. This condition may be experienced shortly after starting treatment and is usually reversible upon discontinuation of treatment. Furthermore, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester of pregnancy, most of which disappeared after discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment should be as short as possible. Following exposure to diclofenac for several days from the 20th\u003csup\u003ea\u003c\/sup\u003e week of gestation onwards, antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered. In case of oligohydramnios or constriction of the ductus arteriosus, treatment with diclofenac should be discontinued. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose - the fetus to: - cardiopulmonary toxicity (constriction\/premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction (see above), which may progress to renal failure with oligo-hydramnios; - the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. Therefore, diclofenac should not be administered during breastfeeding to avoid side effects in the infant. \u003cb\u003eFertility\u003c\/b\u003e As with other NSAIDs, the use of diclofenac can alter female fertility and is not recommended in women wishing to conceive. Discontinuation of diclofenac should be considered in women who have difficulty conceiving or who are undergoing infertility investigations.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatients in whom vision disturbances, dizziness, vertigo, drowsiness or other central nervous system disorders have occurred with the use of diclofenac should refrain from driving vehicles or using machinery.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131218985287,"sku":"035500040","price":12.16,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadvance-25mg-20-bustine-polvere-per-soluzione-orale-farmacia-dottor-tili-1213792344.jpg?v=1767142648"},{"product_id":"voltaren-emulgel-gel-2-180-gr","title":"Voltaren Emulgel Gel 2% 180 Gr","description":"\u003cp\u003eVoltaren Emulgel Gel \u003cstrong\u003epainkiller and anti-inflammatory\u003c\/strong\u003e for \u003cstrong\u003emuscle and joint pain\u003c\/strong\u003e based on Diclofenac (2%). Voltaren Emulgel is a local treatment of \u003cstrong\u003epainful and inflammatory states\u003c\/strong\u003e: of a rheumatic or traumatic nature of the joints, such as \u003cstrong\u003eosteoarthritis and arthritis\u003c\/strong\u003e; of the muscles, in case of \u003cstrong\u003econtractures or injuries\u003c\/strong\u003e; of tendons and ligaments, in the presence of \u003cstrong\u003etendinitis\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Voltaren Emulgel Gel 2% 180 Gr used? What is it for?\u003c\/h3\u003e\u003cp dir=\"\"\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003e100 g of Voltaren Emulgel contain 2.32 g of diclofenac diethylammonium, equivalent to 2 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g of gel), butylated hydroxytoluene (0.2 mg\/g of gel), pungent eucalyptus perfume. For the full list of excipients, see section 6.1.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eButylated hydroxytoluene, carbomers, cocoyl caprylocaprate, diethylamine, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleic alcohol, propylene glycol, pungent eucalyptus perfume, purified water.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr taken?\u003c\/h3\u003e\u003cp dir=\"\"\u003eFor cutaneous use. Adults over 18 years of age, Voltaren Emulgel 2% gel provides pain relief for up to 12 hours: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. Warning: use only for short treatment periods. The duration of treatment depends on the indication for use and the clinical response. The gel should not be used for more than 14 days without medical advice. Consult your doctor if symptoms persist or worsen after 7 days of treatment. Adolescents aged 14 to 18: apply Voltaren Emulgel 2% gel 2 times a day on the area to be treated (preferably in the morning and evening), rubbing lightly. The quantity to be applied depends on the size of the affected part. For example, 2-4 g of Voltaren Emulgel 2% gel (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of ​​400-800 cm^2. After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 2% to dry before showering or bathing. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult a doctor. Children under 14 years: Insufficient data are available on the efficacy and safety of children and adolescents under 14 years (see section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel 2% gel is contraindicated in children under 14 years of age. Elderly (over 65 years): the usual dosage for adults can be used.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Voltaren Emulgel Gel 2% 180 Gr not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp dir=\"\"\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; history of asthma, angioedema, urticaria or acute rhinitis following the intake of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); during the third trimester of pregnancy; use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cp dir=\"\"\u003eSide effects include mild, transient skin reactions at the application site. In very rare cases, allergic reactions may occur. Side effects are listed below by organ, system\/system and MedDRA frequency. Frequencies are defined as: very common (\u003e= 1\/10) common (\u003e= 1\/100 to \u003c1\/10); uncommon (\u003e= 1\/1,000 to \u003c 1\/100); rare (\u003e= 1\/10,000 to \u003c 1\/1,000); very rare (\u003c 1\/10,000) not known (frequency cannot be estimated from the available data). Infections and infestations. Very rare: rash with pustules. Immune system disorders. Very rare: hypersensitivity (including urticaria), angioedema. Respiratory, thoracic and mediastinal disorders. Very rare: asthma. Pathologies of the skin and subcutaneous tissue. Common: dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus; rare: bullous dermatitis; very rare: photosensitivity reaction, allergic reactions; not known: burning sensation at the application site, dry skin. Reporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reaction via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eSince the systemic absorption of diclofenac following topical application is very low, interactions are very unlikely.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Voltaren Emulgel Gel 2% 180 Gr be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp dir=\"\"\u003ePregnancy: the systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: the inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increases from less than 1%, up to approximately 1.5%. The risk is believed to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality; furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors had been administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction, which may progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Diclofenac is contraindicated during the third trimester of pregnancy. Breastfeeding: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of Voltaren Emulgel 2% no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, Voltaren Emulgel 2% must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4 Special warnings and precautions for use).\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThe possibility of systemic adverse events with the application of Voltaren Emulgel 2% cannot be excluded if the preparation is used on large skin areas and for a prolonged period. Voltaren Emulgel 2% must be applied only to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Voltaren Emulgel 2% can be used with non-occlusive dressings, but must not be used with an occlusive dressing that does not allow air to pass through. Important information about some excipients: Voltaren Emulgel 2% gel contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g which may cause skin irritation. Voltaren Emulgel 2% gel contains butylated hydroxytoluene which may cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. Voltaren Emulgel 2% gel contains pungent eucalyptus scent, an aroma which in turn contains benzyl alcohol, citronellol, coumarin, d-limonene, eugenol, geraniol, linalool which may cause allergic reactions.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltaren Emulgel Gel 2% 180 Gr stored?\u003c\/h3\u003e\u003cp dir=\"\"\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Voltaren Emulgel Gel 2% 180 Gr?\u003c\/h3\u003e\u003cp\u003e180 gr\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51131285078343,"sku":"034548230","price":27.08,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-gel-2-180-gr-farmacia-dottor-tili-1213792236.jpg?v=1767133870"},{"product_id":"voltadvancego-25mg-20-capsule-molli","title":"VoltadvanceGo 25mg 20 softgels","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor the short-term symptomatic treatment of: - mild to moderate pain (such as headache, toothache, menstrual pain, rheumatic pain and muscle pain)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eFor VoltadvanceGo 12.5 mg \u003c\/i\u003e Each soft capsule contains diclofenac in the form of 15.38 mg of diclofenac epolamine equivalent to 12.5 mg of diclofenac potassium. \u003ci\u003eFor VoltadvanceGo 25 mg\u003c\/i\u003e Each soft capsule contains diclofenac in the form of 30.76 mg of diclofenac epolamine equivalent to 25 mg of diclofenac potassium. \u003cu\u003eExcipient(s) with known effects: \u003c\/u\u003e \u003ci\u003eFor VoltadvanceGo 12.5 mg\u003c\/i\u003e Sorbitol (E420) maximum 8.02 mg \u003ci\u003eFor VoltadvanceGo 25 mg\u003c\/i\u003e Sorbitol (E420) maximum 10.07 mg For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eCapsule contents: \u003c\/u\u003e Macrogol 600, Anhydrous Glycerol, Purified Water. \u003cu\u003eCapsule:\u003c\/u\u003e Gelatin, Anhydrous glycerol, Liquid sorbitol, partially dehydrated (E420), Purified water, Hydroxypropylbetadex, Sodium hydroxide.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1; • Active gastric or intestinal ulcer, bleeding or perforation; • Alterations of unknown origin in hematopoiesis; • History of gastrointestinal bleeding or perforation, related to previous therapy with NSAIDs; • History of recurrent peptic ulcer\/hemorrhage (two or more distinct episodes of established ulceration or bleeding); • Overt congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease and\/or cerebral vasculopathy; • Last trimester of pregnancy (see section 4.6); • Severe hepatic, renal or cardiac insufficiency (see section 4.4); • Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom acetylsalicylic acid or other NSAIDs trigger attacks of bronchospasm, asthma, urticaria or acute rhinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e Undesirable effects can be minimized by administering the minimum effective dose for the minimum duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use). \u003ci\u003eFor VoltadvanceGo 12.5 mg\u003c\/i\u003e Unless otherwise prescribed, adults and adolescents over 14 years of age should start with 1 or 2 soft capsules and then continue with 1 or 2 soft capsules every 4 to 6 hours, as needed. In any case, no more than 6 soft capsules (equivalent to 75 mg of diclofenac potassium) should be taken in a 24-hour period. \u003ci\u003eFor VoltadvanceGo 25 mg \u003c\/i\u003e Unless otherwise prescribed, adults and adolescents over 14 years of age should start with 1 softgel and subsequently continue with 1 softgel every 4 to 6 hours as needed. In any case, no more than 3 soft capsules (equivalent to 75 mg of diclofenac potassium) should be taken within 24 hours. VoltadvanceGo is intended to be taken for a short period of time. The duration of treatment must be 3 days. If symptoms persist or worsen, consult a doctor. \u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e The use of VoltadvanceGo is not recommended in children and adolescents under 14 years of age. \u003ci\u003e \u003cu\u003eElderly\u003c\/u\u003e \u003c\/i\u003e No particular dosage adjustment is necessary. In view of the possible side effect profile, elderly people should be monitored with particular attention (see section 4.4). \u003ci\u003e \u003cu\u003eKidney damage\u003c\/u\u003e \u003c\/i\u003e Diclofenac is contraindicated in patients with severe renal impairment (see section 4.3). No dose reduction is necessary in patients with mild to moderate reduced renal function. Caution is advised when administering diclofenac to patients with mild to moderate renal impairment (see section 4.4). \u003ci\u003e \u003cu\u003eHepatic impairment\u003c\/u\u003e \u003c\/i\u003e Diclofenac is contraindicated in patients with severe hepatic impairment (see section 4.3). No dose reduction is necessary in patients with mild to moderate hepatic function. Caution is advised when administering diclofenac to patients with mild to moderate hepatic impairment (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e The soft capsules should be swallowed whole with a drink of water. The rate of absorption of diclofenac is reduced when VoltadvanceGo is taken with food. It is therefore recommended not to take the soft capsules during or immediately after meals.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 25°C. Store in the original packaging in order to protect from light and moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eGeneral\u003c\/b\u003e Undesirable effects can be minimized by administering the minimum effective dose for the minimum duration necessary to control symptoms (see section 4.2 and the sections below on gastrointestinal and cardiovascular effects). Concomitant use of VoltadvanceGo with other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, should be avoided in view of the lack of any evidence demonstrating synergistic benefits and the possibility of additional side effects (see section 4.5). On a basic medical level, caution is required in the elderly. In particular, in frail elderly patients or in those with low body weight, the use of the minimum effective dose is recommended. As with other NSAIDs, with diclofenac, in rare cases, allergic reactions, including anaphylactic\/anaphylactoid reactions, may occur, even without previous exposure to the medicine. Hypersensitivity reactions can also progress to Kounis syndrome, a severe allergic reaction that can cause a myocardial infarction. Current symptoms of such reactions may include chest pain occurring in association with an allergic reaction to diclofenac. Like other NSAIDs, diclofenac may mask the signs and symptoms of infection due to its pharmacodynamic properties. \u003cb\u003eGastrointestinal effects\u003c\/b\u003e Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported and may occur at any time during treatment with all NSAIDs, including diclofenac, with or without warning symptoms or previous history of serious gastrointestinal events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients taking diclofenac, the medicine should be discontinued. As with all NSAIDs, including diclofenac, close medical surveillance is mandatory and particular caution should be used when prescribing diclofenac to patients with symptoms suggestive of gastrointestinal (GI) disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8). The risk of GI bleeding is higher with increased doses of NSAIDs and in patients with a history of ulcer, especially if complicated by hemorrhage or perforation. Elderly people have a higher frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation which can be fatal. To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated by hemorrhage or perforation, and in the elderly, treatment should be initiated and maintained at the lowest effective dose. The concomitant use of protective agents (e.g. proton pump inhibitors or misoprostol) should be considered for these patients and also for patients who require concomitant use of medicinal products containing low doses of acetylsalicylic acid (ASA) or other drugs that may increase gastrointestinal risk (see section 4.5). Patients with a history of GI toxicity, particularly older adults, should report any unusual abdominal symptoms (especially GI bleeding). Caution is recommended in patients taking concomitant medicinal products that may increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants, antiplatelet agents or selective serotonin reuptake inhibitors (see section 4.5). Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn's disease as these conditions may be exacerbated (see section 4.8). NSAIDs, including diclofenac, may be associated with an increased risk of gastrointestinal anastomotic leak. Close medical surveillance and caution are recommended when using diclofenac following gastrointestinal surgery. \u003cb\u003eHepatic effects\u003c\/b\u003e When prescribing diclofenac to patients with liver failure, close medical supervision is necessary, as their condition may be exacerbated. As with other NSAIDs, including diclofenac, they may increase the values ​​of one or more liver enzymes. During prolonged treatment with diclofenac, regular checks of liver function are indicated as a precautionary measure. If abnormal liver function parameters persist or worsen, if clinical signs or symptoms consistent with liver disease develop, or if other manifestations occur (e.g. eosinophilia, rash), treatment with diclofenac should be discontinued. Hepatitis with the use of diclofenac can occur without prodromal symptoms. Particular caution should be exercised when using diclofenac in patients with hepatic porphyria, as it could trigger an attack. \u003cb\u003eRenal effects\u003c\/b\u003e Since fluid retention and edema have been reported in association with therapy with NSAIDs, including diclofenac, particular caution is required in cases of cardiac or renal insufficiency, history of hypertension, in the elderly, in patients receiving concomitant treatment with diuretics or with medicinal products that can significantly affect renal function and in those patients with substantial extracellular volume depletion due to any cause, e.g. before or after major surgery (see section 4.3). In such cases, monitoring of renal function is recommended as a precaution when administering diclofenac. Interruption of therapy is normally followed by a return to pre-treatment conditions. \u003cb\u003eSkin effects\u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). In the early stages of therapy patients appear to be at higher risk for these reactions; the onset of the reaction occurs in most cases within the first month of treatment. VoltadvanceGo should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003cb\u003eSLE and mixed connective tissue disease\u003c\/b\u003e There may be an increased risk of aseptic meningitis in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders (see section 4.8). \u003cb\u003eCardiovascular and cerebrovascular effects\u003c\/b\u003e Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and\/or mild congestive heart failure (NYHA class I) since fluid retention and edema have been found in association with NSAID treatment. Clinical trials and epidemiological data consistently indicate a slight increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment. Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking) should be treated with diclofenac only after careful consideration. Since the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the lowest effective daily dose should be used for the shortest possible duration. The response to therapy and the need for improvement of symptoms should be reassessed periodically. \u003cb\u003ePre-existing asthma\u003c\/b\u003e In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary disease or chronic respiratory tract infections (especially if linked to symptoms similar to allergic rhinitis), reactions to NSAIDs such as asthma exacerbations (so-called analgesic intolerance\/analgesic asthma), Quincke's edema or urticaria, are more frequent than in other patients. Special precaution is therefore recommended in such patients (prepare for an emergency). This also applies to patients allergic to other substances, e.g. with skin reactions, itching or hives. Like other drugs that inhibit the activity of prostaglandin synthase, diclofenac epolamine and other NSAIDs can precipitate bronchospasm if administered to patients who suffer from it or with a previous history of bronchial asthma. \u003cb\u003eHematological effects\u003c\/b\u003e VoltadvanceGo is intended for short-term use. During prolonged treatment with diclofenac, as with other NSAIDs, monitoring of blood counts is recommended. Like other NSAIDs, diclofenac can temporarily inhibit platelet aggregation. Patients with defects in haemostasis, bleeding diathesis or haematological abnormalities should be carefully monitored (see section 4.5). \u003cb\u003eMore information\u003c\/b\u003e This medicinal product contains a maximum of 8.02 mg and 10.07 mg of sorbitol in each 12.5 mg and 25 mg capsule, respectively. Sorbitol is a source of fructose. Patients with rare hereditary problems of fructose intolerance should not take this medicine. This medicinal product contains less than 1 mmol (23 mg) sodium per dosage unit, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe following interactions include those observed with other pharmaceutical forms of diclofenac. \u003cb\u003eDigoxin, phenytoin, lithium: \u003c\/b\u003ethe concomitant use of VoltadvanceGo and digoxin, phenytoin or lithium may increase the concentration of these medicines in the blood. Serum lithium concentration should be monitored. Monitoring of serum digoxin and phenytoin concentrations is recommended. \u003cb\u003eDiuretics and antihypertensive agents: \u003c\/b\u003eas with other NSAIDs, concomitant use of diclofenac with diuretics or antihypertensives (e.g. beta-blockers, angiotensin-converting enzyme [ACE] inhibitors) may cause a reduction in their antihypertensive effect. Therefore, the combination should be administered with caution and blood pressure should be monitored periodically in patients, particularly the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter, particularly for diuretics and ACE inhibitors, due to the increased risk of nephrotoxicity (see section 4.4). Concomitant treatment with potassium-sparing drugs may be associated with increased serum potassium levels, which should therefore be monitored frequently. \u003cb\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors and corticosteroids: \u003c\/b\u003ethe concomitant administration of diclofenac and other systemic NSAIDs or corticosteroids may increase the frequency of gastrointestinal side effects such as gastrointestinal ulcers or bleeding (see section 4.4). \u003cb\u003eAnticoagulants and antiplatelet agents: \u003c\/b\u003ecaution is recommended as concomitant administration may increase the risk of bleeding (see section 4.4). Although clinical investigations do not appear to indicate that diclofenac affects the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients treated with diclofenac concomitantly with anticoagulants. Careful monitoring of such patients is therefore recommended. \u003cb\u003eSelective serotonin reuptake inhibitors (SSRIs): \u003c\/b\u003ethe concomitant administration of systemic NSAIDs, including diclofenac, and SSRIs may increase the risk of gastrointestinal bleeding (see section 4.4). \u003cb\u003eAntidiabetics: \u003c\/b\u003eClinical studies have shown that diclofenac can be administered together with oral antidiabetics without influencing their clinical effect. However, isolated cases of hypoglycemic and hyperglycemic effects have been reported which have made it necessary to change the dosage of antidiabetics during treatment with diclofenac. For this reason, monitoring of blood glucose level is recommended as a precautionary measure during concomitant therapy. \u003cb\u003eMethotrexate: \u003c\/b\u003ediclofenac may inhibit the renal tubular clearance of methotrexate, thus increasing the levels of the latter. Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before or after treatment with methotrexate, since blood concentrations of methotrexate and the toxicity of this substance may increase. \u003cb\u003eTacrolimus:\u003c\/b\u003e Nonsteroidal anti-inflammatory drugs (such as diclofenac) may increase the renal toxicity of tacrolimus. \u003cb\u003eCyclosporine: \u003c\/b\u003ediclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the effect on renal prostaglandins. Therefore, it should be administered at lower doses than would be used in patients not treated with ciclosporin. \u003cb\u003eQuinolone antibacterials: \u003c\/b\u003eIsolated cases of convulsions have been reported, which could be due to the concomitant use of quinolones and NSAIDs. \u003cb\u003eColestipol and cholestyramine\u003c\/b\u003e: these drugs may induce a delay or decrease in the absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4-6 hours after the administration of colestipol\/cholestyramine. \u003cb\u003eCardiac glycosides:\u003c\/b\u003e Concomitant use of cardiac glycosides and NSAIDs in patients may exacerbate heart failure, reduce renal glomerular filtration rate and increase plasma levels of glycosides. \u003cb\u003eMifepristone:\u003c\/b\u003e NSAIDs should not be used for 8-12 days after administration of mifepristone because these can reduce its effect. \u003cb\u003ePotent inhibitors of CYP2C9: \u003c\/b\u003eCaution is recommended when prescribing diclofenac concomitantly with potent CYP2C9 inhibitors (such as probenecid, sulfinpyrazone and voriconazole) which could result in a significant increase in peak plasma concentration and exposure to diclofenac, due to inhibition of its metabolism.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe most commonly observed adverse events concern the gastrointestinal tract. Peptic ulcers, perforation or GI bleeding may occur, sometimes fatal, particularly in the elderly (see section 4.4). Adverse reactions (Table 1) are reported in order of frequency, the most frequent first, using the following convention: very common: (≥1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1. Tabular list of adverse reactions\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003ePathologies of the blood and lymphatic system.\u003c\/p\u003e\n\u003cp\u003eVery rare: Thrombocytopenia, leukopenia, pancytopenia, anemia (including haemolytic and aplastic anemia), agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eRare: Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock) Angioneurotic edema (including facial edema).\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Disorientation, depression, insomnia, nightmares, irritability, psychotic reactions.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Headache, dizziness.\u003c\/p\u003e\n\u003cp\u003eRare: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eVery rare: Paraesthesia, memory impairment, convulsions, anxiety, tremors, aseptic meningitis, taste disturbances, cerebrovascular accidents.\u003c\/p\u003e\n\u003cp\u003eEye pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: Vision disturbances, blurred vision, diplopia.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Dizziness.\u003c\/p\u003e\n\u003cp\u003eVery rare: Tinnitus, hearing worsening.\u003c\/p\u003e\n\u003cp\u003eCardiac diseases.\u003c\/p\u003e\n\u003cp\u003eVery rare: Palpitations, chest pain, heart failure, myocardial infarction.\u003c\/p\u003e\n\u003cp\u003eNot known: Kounis syndrome.\u003c\/p\u003e\n\u003cp\u003eVascular pathologies.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypertension, vasculitis.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eRare: Asthma (including dyspnoea).\u003c\/p\u003e\n\u003cp\u003eVery rare: Pneumonia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders.\u003c\/p\u003e\n\u003cp\u003eCommon: Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.\u003c\/p\u003e\n\u003cp\u003eRare: Gastritis, gastrointestinal haemorrhage, haematemesis, haemorrhagic diarrhoea, melena, gastrointestinal ulcer (with or without bleeding or perforation).\u003c\/p\u003e\n\u003cp\u003eVery rare: Colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorders, diaphragm-like intestinal stricture, pancreatitis.\u003c\/p\u003e\n\u003cp\u003eNot known: Ischemic colitis.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders.\u003c\/p\u003e\n\u003cp\u003eUncommon: Increased transaminases.\u003c\/p\u003e\n\u003cp\u003eRare: Hepatitis, jaundice.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hepatic failure.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Skin rash, pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Urticaria.\u003c\/p\u003e\n\u003cp\u003eVery rare: Bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome), exfoliative dermatitis, alopecia, photosensitivity reaction, purpura, allergic purpura.\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Acute renal failure, haematuria, proteinuria, nephrotic syndrome, interstitial nephritis, renal papillary necrosis.\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eRare: Edema.\u003c\/p\u003e\n\u003cp\u003eClinical trials and epidemiological data consistently indicate an increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke) associated with the use of diclofenac, especially at high doses (150 mg\/day) and long-term treatment (for contraindications and special warnings and precautions for use, see sections 4.3 and 4.4).\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e There is no typical clinical picture resulting from diclofenac overdose. Overdose may cause symptoms such as nausea, vomiting, gastrointestinal bleeding, diarrhea, headache, dizziness, drowsiness, tinnitus, unconsciousness or convulsions. In case of significant poisoning, acute renal failure and liver damage are possible. Hypotension, respiratory depression and cyanosis may also occur. \u003cb\u003eTherapeutic measures\u003c\/b\u003e The management of acute poisoning by NSAIDs, including diclofenac, essentially consists of supportive measures and symptomatic treatment, which should be adopted for complications such as hypotension, renal failure, convulsions, gastrointestinal disorder and respiratory depression. Specific therapies, such as forced diuresis, dialysis or hemoperfusion are probably not helpful in eliminating NSAIDs, including diclofenac, due to their strong binding to plasma proteins and their high metabolism. After ingestion of a potentially toxic overdose, the use of activated charcoal may be considered, while after ingestion of a potentially life-threatening overdose, gastric emptying (e.g. vomiting, gastric lavage) may be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis can cause negative effects on pregnancy and\/or embryo\/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation increased from less than 1% to a maximum of approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals treated with a prostaglandin synthesis inhibitor during the period of organogenesis. From the 20th\u003csup\u003ea\u003c\/sup\u003e week of pregnancy onwards, the use of diclofenac could cause oligohydramnios resulting from fetal renal dysfunction. This condition may be experienced shortly after starting treatment and is usually reversible upon discontinuation of treatment. Furthermore, cases of constriction of the ductus arteriosus have been reported following treatment in the second trimester of pregnancy, most of which disappeared after discontinuation of treatment. Therefore, during the first and second trimester of pregnancy, diclofenac should not be administered unless clearly necessary. If diclofenac is used by a woman who is trying to conceive or during the first and second trimesters of pregnancy, the dose should be as low as possible and the duration of treatment should be as short as possible. Following exposure to diclofenac for several days from the 20th\u003csup\u003ea\u003c\/sup\u003e week of gestation onwards, antenatal monitoring for oligohydramnios and ductus arteriosus constriction should be considered. In case of oligohydramnios or constriction of the ductus arteriosus, treatment with diclofenac should be discontinued. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose: the \u003cu\u003efetus\u003c\/u\u003e a: • cardiopulmonary toxicity (constriction\/premature closure of the ductus arteriosus and pulmonary hypertension), • renal dysfunction, which may progress to renal failure with oligo-hydramnios (see above); the \u003cu\u003emother and newborn baby\u003c\/u\u003e, at the end of pregnancy, to: • possible prolongation of bleeding time and an anti-aggregating effect which can occur even at very low doses, • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, VoltadvanceGo is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e Like other NSAIDs, diclofenac passes in small quantities into breast milk. Therefore, diclofenac should not be administered during breastfeeding to avoid side effects in the newborn. \u003cu\u003eFertility\u003c\/u\u003e As with other NSAIDs, the use of diclofenac may impair female fertility and is not recommended in women trying to conceive. In women who have difficulty conceiving or who are undergoing diagnostic tests for infertility, discontinuation of diclofenac should be considered.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThere are generally no effects on the ability to drive and use machinery with the recommended low dose and short duration of treatment. Patients who experience visual disturbances, dizziness, vertigo, drowsiness or other central nervous system disorders while using diclofenac should refrain from driving or using machinery.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131332591943,"sku":"047665068","price":13.76,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadvancego-25mg-20-capsule-molli-farmacia-dottor-tili-1213792059.jpg?v=1767137128"},{"product_id":"voltadol-140mg-5-cerotti-medicati","title":"Voltadol 140mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA medicated plaster contains: active ingredient: diclofenac sodium 140 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eButyl-methacrylate-copolymer-basic; acrylate-vinyl-acetate copolymer; polyethylene glycol 12 stearate; sorbitan oleate; non-woven fabric; silicone paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cb\u003eDosage\u003c\/b\u003e VOLTADOL should only be applied to intact, healthy skin and should not be applied when bathing or showering. VOLTADOL should be used for the shortest possible time. \u003cu\u003eAdults and adolescents aged 16 and over:\u003c\/u\u003e Apply a patch 2 times a day, in the morning and in the evening, on the skin of the area to be treated, for a period of no more than 7 days. Do not exceed the recommended dose. If there is no improvement or worsening of symptoms is reported after 7 days of treatment, reassess the situation (see section 4.4). \u003cu\u003eSpecial populations\u003c\/u\u003e \u003ci\u003e \u003cu\u003eChildren and adolescents under 16 years of age:\u003c\/u\u003e \u003c\/i\u003e VOLTADOL is contraindicated in children and adolescents under 16 years of age (see section 4.3). \u003ci\u003e \u003cu\u003eElderly and patients with hepatic or renal insufficiency\u003c\/u\u003e \u003c\/i\u003e VOLTADOL should be used with caution (see section 4.4). \u003cb\u003eMethod of administration\u003c\/b\u003e 1 - Cut the envelope along the dotted line and remove the patch. \u003cu\u003eFor applying the plaster\u003c\/u\u003e: 2 - Remove one of the two protective sheets. 3 - Apply to the part to be treated and remove the remaining protective sheet. 4 - Exert light pressure with the palm of your hand until it adheres completely to the skin. The patch must be used whole. \u003cu\u003eFor removing the plaster\u003c\/u\u003e: 5 - Wet the patch with water and then lift one edge by pulling gently. 6 - To eliminate any residues of the product, wash the affected area with water using circular movements with your fingers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTADOL have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those observed after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 pack of 10 patches contains 1400 mg of diclofenac sodium). Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children), general supportive therapeutic measures are recommended with the product to be undertaken in case of intoxication with non-steroidal anti-inflammatory drugs. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy\u003c\/i\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios. The mother and the newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003ci\u003eBreastfeeding\u003c\/i\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTADOL no effects on the infant are expected. Due to the lack of controlled studies in women breastfeeding, the administration of VOLTADOL during breastfeeding should only be considered if the expected benefit for the mother outweighs the risk for the child. In this circumstance, Voltadol must not be applied to the breasts of breastfeeding mothers, nor for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTADOL does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51131353891143,"sku":"035520016","price":15.76,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140mg-5-cerotti-medicati-farmacia-dottor-tili-1213791958.jpg?v=1767141090"},{"product_id":"voltadol-unidie-140-mg-5-cerotti-medicati","title":"Voltadol Unidie 140 mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShort-term local treatment (maximum 7 days) of pain associated with muscle strains, sprains or bruises of arms and legs due to blunt trauma in adolescents from 16 years of age and in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEach medicated plaster contains 140 mg of sodium diclofenac. Each medicated plaster contains 2.90 mg of butylated hydroxyanisole (E 320). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eSupport layer:\u003c\/u\u003e Non-woven polyester. \u003cu\u003eAdhesive layer:\u003c\/u\u003e polyacrylate dispersion, tributyl citrate, butylated hydroxyanisole (E 320). \u003cu\u003eProtective layer:\u003c\/u\u003e monosiliconed paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Hypersensitivity to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs [NSAIDs] - Patients who have had attacks of asthma, urticaria or acute rhinitis in the past after the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Patients with active peptic ulcer. - Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. - Third trimester of pregnancy. - Children and adolescents under 16 years of age.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003e \u003cu\u003eAdults and adolescents aged 16 and over\u003c\/u\u003e \u003c\/i\u003e Apply a medicated plaster once a day to the painful area. The maximum daily dose is 1 medicated plaster, even if there are more than one areas to be treated. Therefore, only one painful area can be treated at a time. \u003ci\u003e \u003cu\u003eDuration of use\u003c\/u\u003e \u003c\/i\u003e Voltadol Unidie should be used for the minimum time necessary to control symptoms. The use of the patch must not exceed 7 days. A therapeutic benefit for longer duration administrations has not yet been demonstrated. \u003ci\u003e \u003cu\u003eElderly patients\u003c\/u\u003e \u003c\/i\u003e The medicine should be used with caution in elderly patients as they are more predisposed to side effects (see also section 4.4). \u003ci\u003e \u003cu\u003ePatients with renal or hepatic impairment\u003c\/u\u003e \u003c\/i\u003e For the treatment of patients with renal or hepatic impairment see section 4.4. \u003ci\u003e \u003cu\u003ePediatric population\u003c\/u\u003e \u003c\/i\u003e There are insufficient data on the efficacy and safety of Voltadol Unidie in children and adolescents under 16 years of age (see section 4.3). The patient\/parents of the adolescent are advised to consult a doctor if it is necessary to administer the medicine for more than 7 days to relieve pain or if symptoms worsen. \u003cu\u003eMethod of administration\u003c\/u\u003e Cutaneous use. The medicated plaster must only be applied to intact, healthy skin and must not be applied when bathing or showering. The medicated plaster must not be divided. If necessary, the medicated plaster can be kept in place using an elastic mesh bandage. The medicated plaster must not be used with an occlusive dressing.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore in the original package to protect the medicine from light and moisture.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe medicated plaster must not come into contact with or be applied to the eyes or mucous membranes. Undesirable effects can be reduced by using the lowest effective dose for the shortest possible time (see section 4.2). Bronchospasm may occur in patients who suffer or have suffered in the past from bronchial asthma or allergies. If a rash develops after applying the medicated plaster, treatment should be stopped immediately. After removal of the medicated plaster, patients should be informed of the need to avoid exposure to sunlight or sunlamps, in order to reduce the risk of photosensitization. It is not possible to exclude the possibility of systemic adverse events resulting from the application of diclofenac medicated plaster, if the product is used on large skin surfaces for a prolonged period of time. Although systemic effects may be minimal, the medicated plaster should be used with caution in patients with impaired renal, cardiac or hepatic function, or with a history of peptic ulcer, intestinal inflammation or haemorrhagic diathesis. Non-steroidal anti-inflammatory drugs should be used with caution in elderly patients, as these subjects are more exposed to the onset of side effects. Do not simultaneously administer, topically or systemically, any other medicinal product containing diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs). Butylated hydroxyanisole (E 320) may cause localized skin reactions (e.g. contact dermatitis) or irritation of the eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac with the methods of use of medicated plasters indicated on the label is very low, the risk of developing clinically significant interactions between drugs is negligible.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects are reported based on the following frequency categories:\u003c\/p\u003e\n\u003cp\u003eVery common: ≥1\/10.\u003c\/p\u003e\n\u003cp\u003eCommon: ≥ 1\/100 to \u003c1\/10.\u003c\/p\u003e\n\u003cp\u003eUncommon: ≥1\/1,000 to \u003c1\/100.\u003c\/p\u003e\n\u003cp\u003eRare: ≥1\/10,000 to \u003c1\/1,000.\u003c\/p\u003e\n\u003cp\u003eVery rare: \u003c1\/10,000.\u003c\/p\u003e\n\u003cp\u003eNot known: Frequency cannot be estimated from the available data.\u003c\/p\u003e\n\u003cp\u003eInfections and manifestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular rash.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eThe levels of diclofenac measured in systemic plasma according to the methods of use of the medicated plasters indicated on the label are very low when compared with those detected after oral intake of diclofenac. The risk of developing systemic side effects (such as gastric, hepatic and renal disorders, systemic hypersensitivity reactions), therefore, appears low with the use of the patch. However, if diclofenac is used on large skin surfaces and for long periods of time, the appearance of systemic side effects is possible. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. If serious systemic side effects occur following incorrect use of the drug or accidental overdose (e.g. in children), the appropriate precautionary measures used for intoxication with non-steroidal anti-inflammatory drugs should be applied.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e The systemic concentration of diclofenac following topical administration is lower than that related to oral formulations. Referring to the experience deriving from treatment with systemic NSAIDs, the following is recommended: inhibition of prostaglandin synthesis may lead to negative effects during pregnancy and\/or during embryonic\/fetal development. Data deriving from epidemiological studies suggest an increased risk of spontaneous abortion, cardiac malformations and gastroschisis, following the use of prostaglandin synthesis inhibitors in the first months of pregnancy. The absolute risk of cardiovascular malformations was increased from a value of less than 1% up to a maximum of approximately 1.5%. The risk is thought to increase with increasing dose and duration of treatment. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramniosis; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect, which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Diclofenac, in small quantities, is secreted into breast milk. However, at therapeutic doses of diclofenac medicated plaster, there are no effects on the infant. Given the lack of controlled clinical studies in breastfeeding women, the medicine should be used during breastfeeding only on the advice of a healthcare professional. In this case, Voltadol Unidie should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large skin surfaces or for a prolonged period of time.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVoltadol Unidie does not alter the ability to drive and use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730205999431,"sku":"048717021","price":18.09,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-unidie-140-mg-5-cerotti-medicati-farmacia-dottor-tili-1213791364.jpg?v=1767139832"},{"product_id":"voltalgan-3-50-g-schiuma-cutanea","title":"Voltalgan 3% 50 g skin foam","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003e100 g of skin foam contains:\u003c\/i\u003e Diclofenac 3 g For the complete list of excipients, see section 6.1\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSodium hydroxide, caprylocapric macrogolglycerides, hydrogenated soy lecithin, polysorbate 80, benzyl alcohol, potassium sorbate, disodium phosphate dodecahydrate, all-rac-α-tocopheryl acetate, mint\/eucalyptus fragrance, purified water. \u003ci\u003eEach pressurized container (50 g) contains\u003c\/i\u003e: 47.5 g of solution and 2.5 g of propellant (isobutane; n-butane; propane).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. Patients verified with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds (see section 4.4). Third trimester of pregnancy (see section 4.6). Children and adolescents under the age of 14.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults and adolescents aged 14 and over\u003c\/b\u003e: Apply VOLTALGAN skin foam 1-3 times a day. For each application, spray a circular mass of foam 3-5 centimeters in diameter (equal to approximately 0.75-1.5 grams in weight) onto the palm of your hand, depending on the size of the area to be treated, massaging delicately until completely absorbed. In case of iontophoresis treatment, the product must be applied to the negative pole. VOLTALGAN skin foam can also be used in combination with ultrasound therapy. After application, ask the patient to wash their hands, otherwise they will also be treated with skin foam. Warning: the product must only be used for short treatment periods. If the product is needed for more than 7 days to relieve pain or if symptoms worsen, the doctor should reassess the situation (see section 4.4). \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years of age (see also section 4.3 Contraindications). Therefore the use of Voltalgan skin foam is contraindicated in children under 14 years of age. \u003cb\u003eElderly\u003c\/b\u003e: The usual dosage for adults can be used. \u003ci\u003e \u003cu\u003eHow to use:\u003c\/u\u003e \u003c\/i\u003e Shake before use. With the canister upside down, dispense the desired quantity by pressing the appropriate dispenser. For cutaneous use only.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eStore below 30°C. \u003ci\u003ePressurized container\u003c\/i\u003e: VOLTALGAN contains flammable propellant. Protect against sunlight and do not expose to temperatures above 50°C. Store away from any source of ignition.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of VOLTALGAN cannot be excluded if the preparation is used on large skin areas and for a prolonged period. VOLTALGAN must be applied only to intact, unaffected skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. It is necessary to discontinue treatment if skin rash develops after application of the product. VOLTALGAN can be used with non-occlusive bandages, but must not be used with an occlusive dressing that does not allow air to pass through. In elderly patients and\/or with gastric problems, the concomitant use of systemic anti-inflammatory drugs is not recommended. Asthmatic patients, with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp), react, with asthmatic attacks, local inflammation of the skin, mucosa (Quincke's edema) or urticaria, to antirheumatic treatment carried out with NSAIDs, more often than other patients. The administration of VOLTALGAN must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use of VOLTALGAN, especially if prolonged, can give rise to local sensitization phenomena, which require the interruption of treatment and the adoption of adequate therapeutic measures. To reduce any photosensitivity phenomena, patients should be advised not to expose themselves to direct sunlight or light from sunlamps during use. In case of allergic reactions or more serious adverse reactions, it is necessary to suspend treatment with VOLTALGAN and establish adequate therapy. The use of the medicine in combination with other medicines containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). VOLTALGAN contains 7.5 mg of benzyl alcohol per dose (equivalent to 1.5 grams by weight). Benzyl alcohol may cause allergic reactions and mild local irritation. VOLTALGAN contains an aroma which in turn contains limonene. Limonene can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following topical application is very low. In high-dose and prolonged treatments, keep in mind the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10), uncommon (≥ 1\/1000, \u003c 1\/100), rare (≥ 1\/10,000, \u003c 1\/1,000), very rare (\u003c1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eNot known: Dry skin, burning sensation on application.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions \u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/content\/come-segnalare-una-sospetti-reazione-avversa.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTALGAN have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those seen after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 50 g pressurized foam container contains approximately 1.54 g of diclofenac sodium). In case of accidental ingestion, which gives rise to significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which can progress to renal failure with oligohydroamnios; the mother and the newborn, at the end of pregnancy, to: • possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTALGAN no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only if the expected benefit to the mother outweighs the risk to the baby. In this circumstance, VOLTALGAN must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4). \u003cb\u003eFertility \u003c\/b\u003e No data are available on the effects of diclofenac for topical use on fertility.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTALGAN has no or negligible influence on the ability to drive or use machinery.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206163271,"sku":"037645013","price":15.77,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltalgan-3-50-g-schiuma-cutanea-farmacia-dottor-tili-1213791360.jpg?v=1767139870"},{"product_id":"voltadol-140-mg-10-cerotti-medicati","title":"Voltadol 140 mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory conditions of a rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA medicated plaster contains: active ingredient: diclofenac sodium 140 mg. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eButyl-methacrylate-copolymer-basic; acrylate-vinyl-acetate copolymer; polyethylene glycol 12 stearate; sorbitan oleate; non-woven fabric; silicone paper.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity to the active substance, to acetylsalicylic acid or to other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. Patients with a history of asthma, angioedema, urticaria or acute rhinitis after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. Third trimester of pregnancy (see section 4.6). Patients with active peptic ulcer. Children and adolescents under the age of 16.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cb\u003eDosage\u003c\/b\u003e VOLTADOL should only be applied to intact, healthy skin and should not be applied when bathing or showering. VOLTADOL should be used for the shortest possible time. \u003cu\u003eAdults and adolescents aged 16 and over:\u003c\/u\u003e Apply a patch 2 times a day, in the morning and in the evening, on the skin of the area to be treated, for a period of no more than 7 days. Do not exceed the recommended dose. If there is no improvement or worsening of symptoms is reported after 7 days of treatment, reassess the situation (see section 4.4). \u003cu\u003eSpecial populations\u003c\/u\u003e \u003ci\u003e \u003cu\u003eChildren and adolescents under 16 years of age:\u003c\/u\u003e \u003c\/i\u003e VOLTADOL is contraindicated in children and adolescents under 16 years of age (see section 4.3). \u003ci\u003e \u003cu\u003eElderly and patients with hepatic or renal insufficiency\u003c\/u\u003e \u003c\/i\u003e VOLTADOL should be used with caution (see section 4.4). \u003cb\u003eMethod of administration\u003c\/b\u003e 1 - Cut the envelope along the dotted line and remove the patch. \u003cu\u003eFor applying the plaster\u003c\/u\u003e: 2 - Remove one of the two protective sheets. 3 - Apply to the part to be treated and remove the remaining protective sheet. 4 - Exert light pressure with the palm of your hand until it adheres completely to the skin. The patch must be used whole. \u003cu\u003eFor removing the plaster\u003c\/u\u003e: 5 - Wet the patch with water and then lift one edge by pulling gently. 6 - To eliminate any residues of the product, wash the affected area with water using circular movements with your fingers.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not store above 30°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf VOLTADOL is used for a prolonged period of time, the possibility of systemic adverse events cannot be excluded. VOLTADOL should only be applied to intact, healthy skin, and should not be applied to damaged skin or open wounds. The patches must not come into contact with the eyes or mucous membranes and must not be swallowed. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Treatment should be stopped immediately if a skin rash develops after application of the medicated plaster. Patients with asthma, chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The administration of VOLTADOL must be suspended in women who have fertility problems or who are undergoing fertility investigations. The use, especially if prolonged, of products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt the treatment and establish a suitable therapy. Although systemic absorption is minimal, the use of VOLTADOL is not recommended in women planning to become pregnant. Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. The use of VOLTADOL in combination with other drugs containing diclofenac can give rise to severe skin reactions (Stevens-Johnson syndrome, Lyell syndrome). Given the route of administration, the risk of systemic effects is lower, however the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. NSAIDs should be used with particular caution in elderly patients who are more predisposed to side effects. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. Patients should be advised not to expose themselves to direct sunlight or light from sunlamps for approximately one day after removal of the medicated plaster in order to reduce the risk of photosensitivity.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac following the use of medicated plasters is low. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eReporting of suspected adverse reactions. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCases of overdose with VOLTADOL have been reported, but no systemic adverse effects that may be caused by overdose with oral NSAIDs (e.g. vomiting, diarrhea, dizziness, tinnitus, gastrointestinal bleeding, convulsions) have been reported. However, side effects similar to those observed after an overdose of diclofenac tablets can be expected if topical diclofenac is inadvertently ingested (1 pack of 10 patches contains 1400 mg of diclofenac sodium). Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children), general supportive therapeutic measures are recommended with the product to be undertaken in case of intoxication with non-steroidal anti-inflammatory drugs. Further treatment modalities should take into account the recommendations of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ci\u003ePregnancy\u003c\/i\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios. The mother and the newborn, at the end of pregnancy, are exposed to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003ci\u003eBreastfeeding\u003c\/i\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of VOLTADOL no effects on the infant are expected. Due to the lack of controlled studies in women breastfeeding, the administration of VOLTADOL during breastfeeding should only be considered if the expected benefit for the mother outweighs the risk for the child. In this circumstance, Voltadol must not be applied to the breasts of breastfeeding mothers, nor for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVOLTADOL does not affect the ability to drive or use machines.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":51730206589255,"sku":"035520028","price":23.81,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-voltadol-140-mg-10-cerotti-medicati-farmacia-dottor-tili-1213791022.jpg?v=1767140125"},{"product_id":"voltaren-emulgel-1-120-g-gel","title":"Voltaren Emulgel 1% 120 g gel","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contain 1.16 g of diclofenac diethylammonium, equivalent to 1 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); benzyl benzoate (1 mg\/g gel); Cream 45 perfume. For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDiethylamine, carbomers, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, liquid paraffin, \u003cb\u003eCream 45 perfume\u003c\/b\u003e (contains \u003cb\u003ebenzyl benzoate\u003c\/b\u003e), \u003cb\u003epropylene glycol\u003c\/b\u003e, purified water\u003cb\u003e.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. Warning: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18\u003c\/b\u003e Apply Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. If this product is needed for more than 7 days for pain relief or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e It is contraindicated in children under six 14 years of age. \u003cb\u003eElderly (over 65 years):\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eTube of 60 g, 100 g, 120 g, 150 g gel and 120 g 1% gel with applicator cap\u003c\/u\u003e: Store below 30°C. \u003cu\u003e50 g pressurized container\u003c\/u\u003e: Store below 30°C. Warning: the container is under pressure: store away from direct sunlight, do not puncture or burn the container, even after use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However side effects similar to those observed after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected if topical diclofenac is ingested (1 60 g tube contains the equivalent of 600 mg of sodium diclofenac). In case of ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":51730207375687,"sku":"034548204","price":15.35,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-voltaren-emulgel-1-120-g-gel-farmacia-dottor-tili-1213791095.jpg?v=1767140310"},{"product_id":"voltaren-emulgel-1-gel-60-g","title":"Voltaren Emulgel 1% Gel 60 g","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of the joints (such as osteoarthritis and arthritis), muscles (such as contractures or injuries), tendons and ligaments (such as tendonitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contain 1.16 g of diclofenac diethylammonium, equivalent to 1 g of diclofenac sodium. Excipients with known effects: propylene glycol (50 mg\/g gel); benzyl benzoate (1 mg\/g gel); Cream 45 perfume. For the complete list of excipients, see paragraph 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDiethylamine, carbomers, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, liquid paraffin, \u003cb\u003eCream 45 perfume\u003c\/b\u003e (contains \u003cb\u003ebenzyl benzoate\u003c\/b\u003e), \u003cb\u003epropylene glycol\u003c\/b\u003e, purified water\u003cb\u003e.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e- Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. - Patients in whom asthma, angioedema, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). - Third trimester of pregnancy. \u003cu\u003eChildren and adolescents\u003c\/u\u003e: Use in children and adolescents under 14 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. Warning: use only for short treatment periods. \u003cb\u003eAdolescents aged 14 to 18\u003c\/b\u003e Apply Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e 3 or 4 times a day on the area to be treated, rubbing lightly. The quantity to be applied depends on the size of the affected part. For example 2-4 g of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e (quantity varying in size between a cherry and a walnut) are sufficient to treat an area of 400-800 cm². After application, clean your hands with absorbent paper and then wash them, unless they are the site to be treated. Paper towels should be disposed of in household waste after use. Patients should wait for Voltaren Emulgel 1% to dry before showering or bathing. If this product is needed for more than 7 days for pain relief or if symptoms worsen, consult a doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e Insufficient data are available on efficacy and safety in children and adolescents under 14 years (see also section 4.3 Contraindications). Therefore, the use of Voltaren Emulgel \u003ci\u003e1% gel\u003c\/i\u003e It is contraindicated in children under six 14 years of age. \u003cb\u003eElderly (over 65 years):\u003c\/b\u003e The usual dosage for adults can be used.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eTube of 60 g, 100 g, 120 g, 150 g gel and 120 g 1% gel with applicator cap\u003c\/u\u003e: Store below 30°C. \u003cu\u003e50 g pressurized container\u003c\/u\u003e: Store below 30°C. Warning: the container is under pressure: store away from direct sunlight, do not puncture or burn the container, even after use.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see the summary of product characteristics of systemic forms of diclofenac\u003ci\u003e).\u003c\/i\u003e Topical diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if skin rash develops after application of the product. Topical diclofenac can be used with non-occlusive dressings, but should not be used with an occlusive dressing that does not allow air to pass through. \u003cb\u003eImportant information about some excipients\u003c\/b\u003e \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e contains 200 mg of propylene glycol per dose (4 g) equivalent to 50 mg\/g and 4 mg of benzyl benzoate per dose (4 g) equivalent to 1 mg\/g which may cause skin irritation. \u003cb\u003e \u003ci\u003eVoltaren Emulgel 1% gel contains Cream 45 perfume, an aroma which in turn contains benzyl alcohol, citral, citronellol, coumarin, d-limonene, eugenol, farinasol, geraniol, linalool which may cause allergic reactions.\u003c\/i\u003e \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: very common (≥1\/10), common (≥1\/100, \u003c1\/10); uncommon (≥ 1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known (frequency cannot be estimated from the available data). \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reaction, allergic reactions.\u003c\/p\u003e\n\u003cp\u003eNot known: Burning sensation at the application site, dry skin.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at: http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of topical diclofenac makes overdose very unlikely. However side effects similar to those seen after an overdose of diclofenac tablets\u003ci\u003e,\u003c\/i\u003e can be expected if topical diclofenac is ingested (1 60 g tube contains the equivalent of 600 mg of sodium diclofenac). In case of ingestion resulting in significant systemic side effects, the general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be undertaken. Further treatment modalities, within the short term of ingestion, should take into account clinical indications or the recommendation of the poison control center, where available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac compared to oral formulations is lower after topical administration. Referring to experience with treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis may negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, \u003ci\u003eVoltaren Emulgel 1% gel\u003c\/i\u003e it must not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Novartis","offers":[{"title":"Default Title","offer_id":53137878024519,"sku":"034548178","price":7.49,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/novartis-farma-spa-Voltaren_Emulgel_1_Gel_60_g-farmacia-dottor-tili-1216497345.jpg?v=1774447396"},{"product_id":"voltadvance-25mg-antinfiammatorio-30-compresse","title":"Voltadvance 25mg Anti-inflammatory 30 Tablets","description":"\u003cp\u003e\u003cstrong\u003eVoltadvance 25mg Anti-inflammatory 30 Tablets\u003c\/strong\u003e it's a \u003cstrong\u003eanti-inflammatory and pain-relieving medicine\u003c\/strong\u003e in \u003cstrong\u003efilm-coated tablets\u003c\/strong\u003e. Each tablet contains \u003cstrong\u003ediclofenac sodium\u003c\/strong\u003e \u003cstrong\u003e25 mg\u003c\/strong\u003e, the active ingredient that gives the class its name.\u003c\/p\u003e\u003cp\u003eThe \u003cstrong\u003ediclofenac\u003c\/strong\u003e belongs to \u003cstrong\u003enon-steroidal anti-inflammatory drugs\u003c\/strong\u003e, NSAIDs, and works by inhibiting the synthesis of prostaglandins. In this formulation it is present in the saline form \u003cstrong\u003esodium\u003c\/strong\u003e, which is the one declared by the owner's RCP. The dosage from \u003cstrong\u003e25 mg\u003c\/strong\u003e it is the low one in the range, designed for short-term use without a prescription.\u003c\/p\u003e\u003cp\u003eThe declared scope of use is that of \u003cstrong\u003epains of various kinds\u003c\/strong\u003e: \u003cstrong\u003ejoint pain\u003c\/strong\u003e, \u003cstrong\u003elumbago\u003c\/strong\u003e, \u003cstrong\u003emuscle pain\u003c\/strong\u003e, \u003cstrong\u003eheadache\u003c\/strong\u003e e \u003cstrong\u003etoothache\u003c\/strong\u003e, \u003cstrong\u003emenstrual pain\u003c\/strong\u003e. The tablets are film-coated and swallowed whole.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eVoltadvance\u003c\/strong\u003e is a brand of \u003cstrong\u003eHaleon\u003c\/strong\u003e. The packaging is from \u003cstrong\u003e30 tablets\u003c\/strong\u003e in OPA, aluminum and PVC blisters, and the range includes packs of 10 and 20 tablets and sachets of powder for oral solution at the same dosage.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Voltadvance 25mg Anti-inflammatory 30 Tablets used? What is it for?\u003c\/h3\u003e\u003cp\u003ePain of various kinds such as, for example, joint pain, lumbago, muscle pain, headaches and toothaches, menstrual pain.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Voltadvance 25mg Anti-inflammatory 30 Tablets?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eActive ingredient\u003c\/strong\u003e\u003cbr\u003eOne film-coated tablet contains diclofenac sodium 25 mg.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003cbr\u003ePotassium bicarbonate, mannitol, sodium lauryl sulfate, crospovidone, magnesium stearate, glycerol dibeenate, Clear Opadry composed of hypromellose and macrogol.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow to take Voltadvance 25mg Anti-inflammatory 30 Tablets?\u003c\/h3\u003e\u003cp\u003eAdults and adolescents over 14 years: 1-3 coated tablets per day, with meals, even 2 in a single administration. The maximum daily dose is 75 mg.\u003c\/p\u003e\u003cp\u003eThe coated tablets should be swallowed whole, with water or another liquid.\u003c\/p\u003e\u003cp\u003eDo not exceed 3 days of treatment.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Voltadvance 25mg Anti-inflammatory 30 Tablets not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003cbr\u003eHypersensitivity to the active substance or to any of the excipients. Active gastrointestinal ulcer, bleeding or perforation. History of recurrent peptic ulcer. Severe liver failure or severe kidney failure. Overt congestive heart failure, NYHA class II to IV. Last trimester of pregnancy and breastfeeding. The medicine should not be given to children under 14 years of age.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003cbr\u003eSide effects mainly concern the gastrointestinal system, the liver, the kidney, the cardiovascular system, the blood and the skin. They can be minimized by using the lowest effective dose for the shortest possible duration.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can modify the effect of Voltadvance 25mg Anti-inflammatory 30 Tablets?\u003c\/h3\u003e\u003cp\u003eThe use of diclofenac concomitantly with other systemic NSAIDs should be avoided.\u003c\/p\u003e\u003cp\u003eInteractions are described with lithium, digoxin, diuretics, anticoagulants, selective serotonin reuptake inhibitors, corticosteroids, ACE inhibitors, methotrexate, ciclosporin, quinolone antibiotics, phenytoin and CYP2C9 inhibitors.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Voltadvance 25mg Anti-inflammatory 30 Tablets be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003eDiclofenac is contraindicated during the third trimester of pregnancy. Inhibition of prostaglandin synthesis can negatively affect pregnancy and embryo-foetal development.\u003c\/p\u003e\u003cp\u003eDiclofenac should not be administered during breastfeeding.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Voltadvance 25mg Anti-inflammatory 30 Tablets?\u003c\/h3\u003e\u003cp\u003eAfter 2-3 days of treatment without appreciable results, consult your doctor.\u003c\/p\u003e\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest possible duration.\u003c\/p\u003e\u003cp\u003eThe risk of arterial thrombotic events increases at high doses, equal to or greater than 150 mg per day, and in prolonged treatment. Elderly patients should be followed with particular attention.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Voltadvance 25mg Anti-inflammatory 30 Tablets stored?\u003c\/h3\u003e\u003cp\u003eThis medicinal product does not require any special storage conditions.\u003c\/p\u003e\u003cp\u003eThe validity period is 5 years.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Voltadvance 25mg Anti-inflammatory 30 Tablets?\u003c\/h3\u003e\u003cp\u003e30 film-coated tablets in OPA, aluminium, PVC and aluminum blisters.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Haleon","offers":[{"title":"Default Title","offer_id":54137677349191,"sku":"035500091","price":16.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/haleon-italy-srl-25-mg-compresse-rivestite-con-film-30-compresse-in-blister-opa-al-pvc-al-farmacia-dottor-tili-1244017743.jpg?v=1781245184"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/voltaren.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}